Benzaldehyde 1,4-dioxaspiro[4.4]non-6-en-8-ylhydrazone

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Benzaldehyde 1,4-dioxaspiro[4.4]non-6-en-8-ylhydrazone
• 英文别名: N-[(E)-benzylideneamino]-1,4-dioxaspiro[4.4]non-8-en-7-amine
• 化学式: C₁₄H₁₆N₂O₂
• 分子量: 244.293
• InChiKey: YNZXKXGWLAIMGW-RVDMUPIBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  42.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Benzaldehyde 1,4-dioxaspiro[4.4]non-6-en-8-ylhydrazone 在 吡啶 、 ammonium hydroxide 、 sodium tetrahydroborate 、 camphor-10-sulfonic acid 作用下， 以 乙醇 、 丙酮 为溶剂， 反应 6.83h， 生成
  参考文献：
  名称：

  Synthesis of hexahydrocyclopentimidazol-2-(1H)-one derivatives displaying selective DP-receptor agonist properties

  摘要：

  The rationale for investigating conformationally restricted analogues of BW245C as DP-receptor ligands and the syntheses of three such racemic bicyclic imidazolidinone analogues are described. Compounds 7 (BW587C), 8 (BW480C85), and 9 (BW572C85) were found to be potent inhibitors of human platelet aggregation and selective DP-receptor agonists in washed platelet and jugular vein isolated tissue assays.

  DOI：

  10.1016/0968-0896(95)00173-5
• 作为产物：
  描述：

  7-溴-1,4-二氧杂螺[4.4]壬-8-烯 、 苯甲醛腙 以 甲苯 为溶剂， 以55%的产率得到Benzaldehyde 1,4-dioxaspiro[4.4]non-6-en-8-ylhydrazone
  参考文献：
  名称：

  Synthesis of hexahydrocyclopentimidazol-2-(1H)-one derivatives displaying selective DP-receptor agonist properties

  摘要：

  The rationale for investigating conformationally restricted analogues of BW245C as DP-receptor ligands and the syntheses of three such racemic bicyclic imidazolidinone analogues are described. Compounds 7 (BW587C), 8 (BW480C85), and 9 (BW572C85) were found to be potent inhibitors of human platelet aggregation and selective DP-receptor agonists in washed platelet and jugular vein isolated tissue assays.

  DOI：

  10.1016/0968-0896(95)00173-5

文献信息

• N-amino bicyclic compounds
  申请人：Burroughs Wellcome Co.

  公开号：US05147885A1

  公开（公告）日：1992-09-15

  N-amino hexahydrocyclopenta imidazole-2(1H)-one derivatives useful for treating or preventing thrombo-embolic disorders and ocular diseases characterized by increased ocular pressure.

  N-氨基六氢环戊咪唑-2(1H)-酮衍生物，用于治疗或预防由增加眼压引起的血栓栓塞性疾病和眼部疾病。
• Amino bicyclic compounds
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0458642A1

  公开（公告）日：1991-11-27

  The present invention is concerned with compounds of formula (I) wherein    X is a sulphur atom or oxygen atom or a group -NR¹- or -CR¹R²-, in the alpha- or beta-configuration, where R¹ and R² are hydrogen or straight or branched C₁₋₅ alkyl;    X¹ is a C₁₋₅ straight chain or branched alkylene group, a C₃₋₅ straight chain or branched alkenylene group or a substituted or unsubstituted C₆ or C₁₀ aromatic group, the optional substituents on the aromatic group being one or more of C₁₋₄ alkyl, C₁₋₄ alkoxy, nitro, halo and trihalomethyl;    X² is a cyano, carboxyl, carboxamide, hydroxymethyl, C₂₋₅ alkoxycarbonyl, or 5-tetrazolyl group;    Z¹ is a group selected from -NH-CH₂-R³ and -N=CO-R³ wherein R³ is a group selected from -CO-Y and -CH(Y¹)Y, Y being a group selected from C₃₋₈ alkyl, C₃₋₈ alkenyl, phenyl-C₁₋₄ alkyl and phenyl (wherein the phenyl group in both cases is optionally substituted by one or more groups independently selected from C₁₋₄ alkyl, C₁₋₄ alkoxy, nitro, halo and trihalomethyl), cycloalkyl of from 4 to 8 carbon atoms and 5- and 6-membered heterocyclic radicals containing at least one oxygen, sulphur, or nitrogen heteroatom and Y¹ being a group selected from hydroxy, hydrogen, C₁₋₄ alkoxy and C₁₋₅ alkanoyloxy;    Z² is hydrogen, C₁₋₁₂ alkyl (straight or branched), C₂₋₁₂ alkenyl or alkynyl, C₆ or C₁₀ aryl or C₆ or C₁₀ aryl-C₁₋₁₂ alkyl wherein the aryl group is optionally substituted by one or more groups independently selected from phenyl, C₁₋₄ alkyl, C₁₋₄ alkoxy, nitro, halo and trihalomethyl) or cycloalkyl of from 3 to 5 carbon atoms; and salts, esters and other physiologically functional derivatives thereof. The preparation of these compounds, medicaments containing them and their use as therapeutic agents are also within the scope of the invention.

  本发明涉及式 (I) 的化合物 其中 X 是硫原子或氧原子或基团 -NR¹- 或 -CR¹R²-，呈 α- 或 β-构型，其中 R¹ 和 R² 是氢或直链或支链 C₁₋₅烷基； X¹ 是 C₁₋₅ 直链或支链亚烷基、C₃₋₅ 直链或支链烯基或取代或未取代的 C₆ 或 C₁₀ 芳基、芳香基团上的任选取代基为 C₁₋₄烷基、C₁₋₄烷氧基、硝基、卤代和三卤甲基中的一个或多个； X² 是氰基、羧基、羧酰胺基、羟甲基、C₂₋₅ 烷氧基羰基或 5-四唑基； Z¹ 是选自 -NH-CH₂-R³ 和 -N=CO-R³ 的基团，其中 R³ 是选自 -CO-Y 和 -CH(Y¹)Y 的基团，Y 是选自 C₃₋₈ 烷基的基团、C₃₋₈烯基、苯基-C₁₋₄烷基和苯基（其中这两种情况下的苯基可选择被一个或多个独立选自 C₁₋₄ 烷基的基团取代）、C₁₋₄烷氧基、硝基、卤代和三卤甲基）、4 至 8 个碳原子的环烷基以及含有至少一个氧、硫或氮杂环基的 5 和 6 元杂环基中任选取代的一个或多个基团、Y¹ 是选自羟基、氢、C₁₋₄ 烷氧基和 C₁₋₅ 烷酰氧基的基团； Z² 是氢、C₁₋₁₂烷基（直链或支链）、C₂₋₁₂烯基或炔基、C₆ 或 C₁₀ 芳基或 C₆ 或 C₁₀ 芳基-C₁₋₁₂烷基，其中芳基任选被一个或多个独立选自苯基的基团取代、C₁₋₄烷基、C₁₋₄烷氧基、硝基、卤代和三卤甲基）或 3 至 5 个碳原子的环烷基； 及其盐类、酯类和其他生理功能衍生物。 这些化合物的制备、含有这些化合物的药物及其作为治疗剂的用途也属于本发明的范围。
• US5147885A
  申请人：——

  公开号：US5147885A

  公开（公告）日：1992-09-15
• Synthesis of hexahydrocyclopentimidazol-2-(1H)-one derivatives displaying selective DP-receptor agonist properties
  作者：Paul Barraclough、Mary L. Bolofo、Heather Giles、Janet Gillam、C. John Harris、Michael G. Kelly、Paul Leff、Alan McNeill、Alan D. Robertson、Ray J. Stepney、Brendan J.R. Whittle

  DOI：10.1016/0968-0896(95)00173-5

  日期：1996.1

  The rationale for investigating conformationally restricted analogues of BW245C as DP-receptor ligands and the syntheses of three such racemic bicyclic imidazolidinone analogues are described. Compounds 7 (BW587C), 8 (BW480C85), and 9 (BW572C85) were found to be potent inhibitors of human platelet aggregation and selective DP-receptor agonists in washed platelet and jugular vein isolated tissue assays.